VIVIMEDLAB
Vivimed Labs financials
- Market cap
- ₹51 Cr
- Sector
- Healthcare
What Vivimed Labs Limited does
Vivimed Labs develops and manufactures generic and branded-generic pharmaceutical formulations — tablets, sachets, oral liquids and ophthalmic products — sold through export/regulated-market and domestic branded channels, and also provides contract manufacturing services to other pharmaceutical companies. It began in 1988 as a formulation contract manufacturer and later added API/bulk-drug manufacturing at Bidar, Karnataka (1991), before building out an API-CDMO subsidiary (UQUIFA) and a specialty-chemicals business through acquisitions. The company has since divested/monetised the specialty-chemicals business (personal care to Clariant in 2016; hair-dye and photochromic dyes in 2019) and its stake in UQUIFA (2020–2024), refocusing on the formulations (FDF) business.
Segments
- Export / Regulated-Markets Formulations
- Domestic Branded Business
- Contract Manufacturing (CDMO)
- Manufacturing facilities
- 5 advanced, certified facilities
- R&D centre
- 1 dedicated R&D centre supporting formulation development
- Quality/regulatory certifications
- Health Canada, PIC/S GMP approved
- Export markets/geographies (FY25)
- Canada, EU, CIS, GCC and ROW countries incl. Bolivia, Chile, Vietnam, Tanzania, Philippines, Saudi Arabia, Azerbaijan, Kyrgyzstan, Ukraine, Uzbekistan, Zambia, Mexico
- New R&D / product-development projects signed (FY25)
- 16
- Original manufacturing site
- Bidar, Karnataka — API/bulk-drug plant commissioned 1991
Quarterly results
Q4 FY26: revenue down 65.2%, net profit down 3450.0% against the same quarter last year.
| Line item | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 25 | 22 | 34 | 23 | 18 −28% | 19 −14% | 12 −65% | 8 −65% |
| EBITDA | -11 | -1 | 0 | -2 | -1 +91% | -1 +0% | -11 | -137 −6750% |
| Net profit | -15 | -5 | -7 | -4 | -6 +60% | -7 −40% | -17 −143% | -142 −3450% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +21.8% 1Y
1Y: ₹4.95 on 31 Jul 2023 → ₹6.03. High ₹26.6 (18 Dec 2025), low ₹4.88 (10 Aug 2026).
Financials, as filed
Revenue fell 35.3% a year over 2 years, FY24 to FY26. Operating margin narrowed to -263.2%.
| Year ending | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹136 Cr | ₹104 Cr | ₹57 Cr |
| Operating profit | ₹-33 Cr | ₹-14 Cr | ₹-150 Cr |
| Operating margin | -24.3% | -13.5% | -263.2% |
| Interest | ₹2 Cr | ₹1 Cr | ₹5 Cr |
| Depreciation | ₹17 Cr | ₹19 Cr | ₹18 Cr |
| Net profit | ₹-45 Cr | ₹-31 Cr | ₹-172 Cr |
| Net margin | -33.1% | -29.8% | -301.8% |
| Cash from operations | ₹-97 Cr | ₹6 Cr | — |
| Free cash flow | ₹-99 Cr | ₹2 Cr | — |
| ROCE | -9.0% | -6.0% | -47.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Equity capital | ₹17 Cr | ₹17 Cr | ₹17 Cr | ₹17 Cr | ₹17 Cr | ₹17 Cr |
| Reserves | ₹537 Cr | ₹508 Cr | ₹441 Cr | ₹117 Cr | ₹73 Cr | ₹-65 Cr |
| Borrowings | ₹304 Cr | ₹323 Cr | ₹357 Cr | ₹377 Cr | ₹375 Cr | ₹384 Cr |
| Other liabilities | ₹210 Cr | ₹247 Cr | ₹258 Cr | ₹286 Cr | ₹217 Cr | ₹588 Cr |
| Total liabilities | ₹1.1k Cr | ₹1.1k Cr | ₹1.1k Cr | ₹796 Cr | ₹681 Cr | ₹924 Cr |
| Fixed assets | ₹356 Cr | ₹416 Cr | ₹429 Cr | ₹343 Cr | ₹326 Cr | ₹393 Cr |
| Capital work in progress | ₹70 Cr | ₹58 Cr | ₹40 Cr | ₹21 Cr | ₹21 Cr | ₹21 Cr |
| Investments | ₹88 Cr | ₹161 Cr | ₹161 Cr | ₹161 Cr | ₹59 Cr | ₹168 Cr |
| Other assets | ₹554 Cr | ₹459 Cr | ₹442 Cr | ₹271 Cr | ₹276 Cr | ₹342 Cr |
| Total assets | ₹1.1k Cr | ₹1.1k Cr | ₹1.1k Cr | ₹796 Cr | ₹681 Cr | ₹924 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Mar 2026
Since Mar 2025, promoters trimmed −13.37 pp while the public added +13.36 pp. The shareholder count shrank 3% to 47,492.
- Promoters
- 7.6%
- FIIs
- 1.6%
- Government
- 0.1%
- Public
- 90.7%
Since Mar 2025
- Promoters −13.37 pp
- Public +13.36 pp
- FIIs 0.00 pp
How it drifted, 12 quarters
Over this window promoters fell from 20.9% to 7.6% — −13.4 pp.
Ownership split by quarter, oldest first. Jun '23: Promoters 20.9%, FIIs 1.6%, Government 0.1%, Public 77.3%.Sep '23: Promoters 20.9%, FIIs 1.6%, Government 0.1%, Public 77.3%.Dec '23: Promoters 20.9%, FIIs 1.6%, Government 0.1%, Public 77.3%.Mar '24: Promoters 20.9%, FIIs 1.6%, Government 0.1%, Public 77.3%.Jun '24: Promoters 20.9%, FIIs 1.6%, Government 0.1%, Public 77.3%.Sep '24: Promoters 20.9%, FIIs 1.6%, Government 0.1%, Public 77.3%.Dec '24: Promoters 20.9%, FIIs 1.6%, Government 0.1%, Public 77.3%.Mar '25: Promoters 20.9%, FIIs 1.6%, Government 0.1%, Public 77.3%.Jun '25: Promoters 7.8%, FIIs 1.6%, Government 0.1%, Public 90.5%.Sep '25: Promoters 7.8%, FIIs 1.6%, Government 0.1%, Public 90.5%.Dec '25: Promoters 7.8%, FIIs 1.6%, Government 0.1%, Public 90.5%.Mar '26: Promoters 7.6%, FIIs 1.6%, Government 0.1%, Public 90.7%.
Who bought this quarter
since Dec 2025
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Amicorp Capital (Mauritius) Limited FPI fund newly disclosed 1.47% held
- Jagat Foods Private Limited newly disclosed 1.12% held
The same filing shows 2 holders trimming and 2 off the list — both are in the register beside this.
Who is on the register
Named in the Mar 2026 filing
Every holder of Vivimed Labs Limited above SEBI's 1% disclosure line, and what changed since Dec 2025.
| Holder | Stake | Change |
|---|---|---|
| Kitara Piin 1102 | 9.37% | unchanged |
| Varalwar Sandeep | 2.81% | unchanged |
| William F Harvey | 1.65% | unchanged |
| Sameer Mahendra Sampat | 1.64% | unchanged |
| Subhash Varalwar | 1.63% | unchanged |
| Amicorp Capital (Mauritius) Limited FPI fund | 1.47% | newly disclosed |
| Ashish Bharatkumar Shah | 1.42% | unchanged |
| Monarch Networth Finserve Private Limited | 1.24% | unchanged |
| Jagat Foods Private Limited | 1.12% | newly disclosed |
| Sheetal Varalwar | 0.83% | unchanged |
| Bbr Projects Private Limited | 0.52% | unchanged |
| Manohar Rao Varalwar | 0.52% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Vivimed Labs Limited
Guides on how to read this kind of business and the numbers that matter.